FLUVOXAMINE-HEXAL™ 100 mg film coated tablets

Country: South Africa

Language: English

Source: South African Health Products Regulatory Authority (SAHPRA)

Buy It Now

Available from:

Hexal

Patient Information leaflet

                                INDICATIONS [/za_1104.html#1]
  [/za_1104.html#1]     [/za_1104.html#1]
CONTRA-INDICATIONS [/za_1104.html#1]
      [/za_1104.html#1]
DOSAGE [/za_1104.html#1]
      [/za_1104.html#1]
SIDE-EFFECTS [/za_1104.html#1]
  [/za_1104.html#1]     [/za_1104.html#1]
PREGNANCY [/za_1104.html#1]
      [/za_1104.html#1]
OVERDOSE [/za_1104.html#1]
    
IDENTIFICATION [/za_1104.html#1]
  [/za_1104.html#1]    PATIENT INFORMATION
FLUVOXAMINE-HEXAL™ 100 MG FILM COATED TABLETS 
SCHEDULING STATUS:
S5
PROPRIETARY NAME
(and dosage form):
FLUVOXAMINE-HEXAL™ 100 MG FILM COATED TABLETS 
COMPOSITION
Each 100 mg tablet contains 
FLUVOXAMINE
 maleate (5-methoxy-4’-(trifluoromethyl)valerophenone(E)-O-(2-aminoethyl)-
oxime maleate (1:1)) 100 mg
PHARMACOLOGICAL CLASSIFICATION 
A.1.2 Psychoanaleptics (antidepressants)
PHARMACOLOGICAL ACTION
The mechanism of action of fluvoxamine is presumably linked to its serotonin re-uptake inhibition in brain neurons.
PHARMACOKINETICS:
Fluvoxamine is variably absorbed after oral administration. Bioavailability is about 50%. Fluvoxamine is extensively
metabolised in the liver. The metabolites are pharmacologically inactive and are renally excreted. The elimination half-
life is 15 to 20 hours. Steady state plasma levels are reached within 2 weeks of treatment with a constant dose.
INDICATIONS
•
FLUVOXAMINE-HEXAL is indicated for the treatment of major depressive disorders and for short-term treatment of
severe, disabling obsessive-compulsive disorders, where the obsessions or compulsions significantly interfere with
social or occupational functioning, cause severe distress or are time-consuming.
CONTRA-INDICATIONS
• Hypersensitivity to fluvoxamine or any of the ingredients of 
FLUVOXAMINE-HEXAL
•
MAO INHIBITORS: FLUVOXAMINE-HEXAL should not be used in combination with MAO inhibitors or within 2 weeks of
terminat
                                
                                Read the complete document
                                
                            

Similar products

Search alerts related to this product